+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Histone Deacetylase Inhibitors Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • ID: 4899035
  • Report
  • November 2019
  • Region: Global
  • 100 Pages
  • Infinium Global Research

FEATURED COMPANIES

  • AstraZeneca plc
  • Celegene Corporation
  • Merck & Co., Inc.
  • Novartis International AG
  • Oncolys BioPharma Inc.
The report on the global histone deacetylase inhibitors market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global histone deacetylase inhibitors market to grow with a CAGR of 5.9% over the forecast period from 2019-2025. The study on histone deacetylase inhibitors market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on histone deacetylase inhibitors market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global histone deacetylase inhibitors market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global histone deacetylase inhibitors market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers
  • A surge in demand for improved and effective therapies
  • Rising prevalence of cancer globally
  • High affinity and specificity of the HDAC enzyme

2) Restraints
  • Uncertainty and reimbursement issues with respect to HDAC inhibitors

3) Opportunities
  • Surge in investments in HDAC manufacturing and growing research and development activities in HDACS

Research Methodology

A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global histone deacetylase inhibitors market is segmented on the basis of class, and applications.

The Global Histone Deacetylase Inhibitors Market by Class
  • Class I HDACs
  • Class II HDACs
  • Class III HDACs

The Global Histone Deacetylase Inhibitors Market by Applications
  • Neurology
  • Oncology
  • Central Nervous System Disorders
  • Other Diseases

Company Profiles

The companies covered in the report include
  • Novartis International AG
  • Celegene Corporation
  • AstraZeneca plc
  • Acetylon Pharmaceuticals, Inc.
  • FORUM Pharmaceuticals, Inc.
  • Celleron Therapeutics Ltd.
  • Merck & Co., Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Shenzhen Chipscreen Biosciences Co. Ltd.
  • Oncolys BioPharma Inc.
  • Other Companies

What does this report deliver??
1. Comprehensive analysis of the global as well as regional markets of the histone deacetylase inhibitors market.
2. Complete coverage of all the segments in the histone deacetylase inhibitors market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global histone deacetylase inhibitors market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca plc
  • Celegene Corporation
  • Merck & Co., Inc.
  • Novartis International AG
  • Oncolys BioPharma Inc.

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
2.1. Histone Deacetylase Inhibitors Market Highlights
2.2. Histone Deacetylase Inhibitors Market Projection
2.3. Histone Deacetylase Inhibitors Market Regional Highlights
3. Global Histone Deacetylase Inhibitors Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Class
3.4.2. Growth Matrix Analysis by Applications
3.4.3. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Histone Deacetylase Inhibitors Market
4. Histone Deacetylase Inhibitors Market Macro Indicator Analysis
5. Global Histone Deacetylase Inhibitors Market by Class
5.1. Class I HDACs
5.2. Class II HDACs
5.3. Class III HDACs
6. Global Histone Deacetylase Inhibitors Market by Applications
6.1. Neurology
6.2. Oncology
6.3. Central Nervous System Disorders
6.4. Other Diseases
7. Global Histone Deacetylase Inhibitors Market by Region 2019-2025
7.1. North America
7.1.1. North America Histone Deacetylase Inhibitors Market by Class
7.1.2. North America Histone Deacetylase Inhibitors Market by Applications
7.1.3. North America Histone Deacetylase Inhibitors Market by Country
7.2. Europe
7.2.1. Europe Histone Deacetylase Inhibitors Market by Class
7.2.2. Europe Histone Deacetylase Inhibitors Market by Applications
7.2.3. Europe Histone Deacetylase Inhibitors Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Histone Deacetylase Inhibitors Market by Class
7.3.2. Asia-Pacific Histone Deacetylase Inhibitors Market by Applications
7.3.3. Asia-Pacific Histone Deacetylase Inhibitors Market by Country
7.4. RoW
7.4.1. RoW Histone Deacetylase Inhibitors Market by Class
7.4.2. RoW Histone Deacetylase Inhibitors Market by Applications
7.4.3. RoW Histone Deacetylase Inhibitors Market by Sub-region
8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Histone Deacetylase Inhibitors Market
8.2. Companies Profiled
8.2.1. Novartis International AG
8.2.2. Celegene Corporation
8.2.3. AstraZeneca plc
8.2.4. Acetylon Pharmaceuticals, Inc.
8.2.5. FORUM Pharmaceuticals, Inc.
8.2.6. Celleron Therapeutics Ltd.
8.2.7. Merck & Co., Inc.
8.2.8. Spectrum Pharmaceuticals, Inc.
8.2.9. Shenzhen Chipscreen Biosciences Co. Ltd.
8.2.10. Oncolys BioPharma Inc.
8.2.11. Other Companies
9. Appendix
9.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
  • Novartis International AG
  • Celegene Corporation
  • AstraZeneca plc
  • Acetylon Pharmaceuticals, Inc.
  • FORUM Pharmaceuticals, Inc.
  • Celleron Therapeutics Ltd.
  • Merck & Co., Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Shenzhen Chipscreen Biosciences Co. Ltd.
  • Oncolys BioPharma Inc.
Note: Product cover images may vary from those shown